Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Osiris Therapeutics, Inc. announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed.

The patent at issue covers the administration of mesenchymal stem cells (MSCs), including Prochymal® (remestemcel-L), for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.

As acknowledged in the Australian Official Journal of Patents Supplement, all claims to the patent will be maintained in full. The claims specifically include the use of allogeneic MSCs, an attribute central to making an off-the-shelf MSC product possible.

In 2012, Prochymal, an intravenous formulation of MSCs, became the world's first stem cell drug to gain approval by an internationally recognized regulatory authority. Prochymal is also the first drug approved for acute graft versus host disease (GvHD) - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis. Prochymal is now approved in Canada and New Zealand, and is currently available in seven other countries including the United States under an Expanded Access Program.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Phase II Trial for Type 1 Diabetes
The company is evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed type 1 diabetes in this first-of-its kind trial conducted in partnership with JDRF.
Tuesday, January 03, 2012
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Osiris held a successful pre-Biologics License Application meeting for Prochymal used in the treatment of graft-versus-host disease.
Monday, January 19, 2009
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
The trial will assess safety and efficacy of Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease.
Friday, December 05, 2008
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
The acquisition includes proprietary adult stem cell bone graft product and processing facility.
Tuesday, May 13, 2008
Osiris Announces Positive Results in Stem Cell Trial to Treat Heart Disease
Osiris reports the results of a double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of the intravenous administration an adult mesenchymal stem cell therapy.
Monday, March 26, 2007
Osiris Recieves FDA Fast Track status and Clearance to Start Phase III trials for Crohn’s Disease Stem Cell Therapy
Company’s Phase III program will be the last phase of testing before it seeks full approval for Crohn’s Disease.
Monday, January 15, 2007
Scientific News
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
Cirrhosis-Causing Cells Converted to Healthy Liver Cells in Mice
New approach that repairs liver from within may be more efficient than cell transplants.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!